What is pembrolizumab (Keytruda) and is it used for Prostate Cancer

Pembrolizumab (Keytruda) for Prostate Cancer

What Is Pembrolizumab?

Pembrolizumab, sold under the brand name Keytruda, is an immune checkpoint inhibitor — a type of immunotherapy drug that works by "releasing the brakes" on your immune system.

Here's how it works in plain terms:

The Basic Mechanism: Cancer cells have a clever survival trick. They display a protein called PD-L1 on their surface that sends a "stop" signal to your immune cells (specifically T-cells). This signal essentially tells your body's cancer-fighting cells: "Don't attack me, I'm friendly." Pembrolizumab blocks this deceptive signal by binding to a protein called PD-1 on T-cells. By blocking this interaction, the drug removes the "off switch," allowing your immune system to recognize and attack the cancer cells.

Is Pembrolizumab Used for Prostate Cancer?

Yes, but with important limitations. According to NCCN Guidelines and recent clinical evidence, pembrolizumab is FDA-approved for prostate cancer, but only for specific patient populations with particular genetic markers.

When Pembrolizumab Is Approved for Prostate Cancer:

Pembrolizumab is recommended for patients with metastatic castrate-resistant prostate cancer (cancer that has spread and no longer responds to hormone therapy) who have one of these specific biomarkers:

1. MSI-High (Microsatellite Instability High) — This means your tumor has a defect in DNA mismatch repair, leading to many mutations. About 3-5% of prostate cancers have this feature.

2. TMB-High (Tumor Mutational Burden High) — This indicates your cancer has a high number of mutations overall.

3. Mismatch Repair Deficiency (dMMR) — Similar to MSI-high, this shows your tumor's DNA repair system isn't working properly.

Important Clinical Context:

According to experts in the field, prostate cancer is considered an "immunologically cold" tumor, meaning it naturally has fewer immune cells infiltrating it compared to cancers like melanoma or lung cancer. This affects how well pembrolizumab works.

Response rates are modest:

• For patients with MSI-high prostate cancer, the response rate to pembrolizumab alone is approximately 50%, but the durable response rate (lasting benefit) is only about 25%.
• This is very different from colorectal cancer with MSI-high, where response rates are much higher (around 90%).

When Pembrolizumab Is NOT Recommended:

According to NCCN Guidelines, pembrolizumab is not recommended as a first-line treatment for most prostate cancer patients because:

• Most prostate cancers don't have these specific biomarkers
• Response rates in unselected patients are very low (around 10%)
• Keytruda failed in three Phase 3 clinical trials in prostate cancer when used without patient selection based on biomarkers

Treatment Sequencing

If you have metastatic castrate-resistant prostate cancer and are being considered for pembrolizumab, NCCN Guidelines indicate it's typically used after you've already received:

• Docetaxel (chemotherapy)
• Novel hormone therapies (like abiraterone or enzalutamide)

Emerging Combination Approaches

Current research suggests pembrolizumab may work better when combined with other therapies, such as:

• T-cell bispecifics (newer immunotherapy drugs that act like "heat-seeking missiles" to bring immune cells directly to cancer cells)
• Radiation therapy (which may help activate the immune system)
• CTLA-4 inhibitors (like ipilimumab/Yervoy, another type of immune checkpoint inhibitor)

According to recent clinical discussions, researchers believe that T-cell bispecifics combined with pembrolizumab may become the backbone of future immunotherapy approaches for prostate cancer, potentially improving that 25% durable response rate.

Questions to Ask Your Oncologist

If pembrolizumab is being discussed for your care:

1. "Have I been tested for MSI-high, mismatch repair deficiency, or TMB-high status?" — These biomarkers determine whether pembrolizumab is appropriate for you.

2. "If I have one of these biomarkers, what is the expected response rate for my specific situation?"

3. "Are there clinical trials combining pembrolizumab with other therapies that I might be eligible for?"

4. "What is the plan if pembrolizumab doesn't work or stops working?" — This is important because using pembrolizumab may affect your eligibility for other immunotherapy trials.

5. "Should we consider combination therapy rather than pembrolizumab alone?" — Given the modest durable response rates, combination approaches are increasingly being studied.

Key Takeaway

Pembrolizumab is an important tool for prostate cancer, but it's not a one-size-fits-all treatment. Your specific genetic biomarkers determine whether it's appropriate for you. If you have the right biomarkers, it offers a meaningful option, but response rates are modest compared to other cancer types. Your oncologist will determine the most appropriate approach for YOUR specific case based on your complete clinical picture, including your biomarker status, prior treatments, and overall health.

---

Sources:

• NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer
• "Update on Immunotherapies for Metastatic Castrate Resistant Prostate Cancer" (Sumit Subudhi, MD, PhD)
• "How MSI and Other Tests Can Guide Immunotherapies for Cancer Treatment" (Heather Tomlinson)

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.